Clinical Trial Search

Primary: Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI) — 8; 30; 10 percentage of participants

Primary: Percentage of Participants With Asthma at 6 Years of Age: Overall and by Prognostic Factor — 6.1; 11.2; 3.1; 9.6 percentage of participants

Primary: Percentage of Infant Participants With Medically Attended Lower Respiratory Tract Illness (MA-LRTI) Cases Due to RSV Occurring Within 90 Days After Birth (Efficacy)…

Primary: The Number of Sampling Visits on Which Participants Are Willing to Undergo Nasosorption and/or NPA Sampling — 124; 60; 0; 0 Sampling visits

Primary: Circulating RI-001 Titer — 9.24; 4.85; 1.42 Fold Change

Primary: Incidence Rates of First Episode of Respiratory Syncytial Virus (RSV) Respiratory Tract Infection (RTI) [Period 1] — 7.93 Cases per 100 person-years

Primary: Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower…

Primary: Number of Subjects With Any Solicited Local Adverse Events (AEs) During a 7-day Follow-up Period After the First Vaccination (Administered at Day 1) — 5; 6; 0; 22…

Primary: Percentage of Placebo Receiving Pediatric Participants With Vaccine Virus Detected in Nasal Swabs After the First Vaccination — 0; 0; 0; 0 percentage of participants

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade (RSV-seropositive Participants) — 10; 9; 4; 0 Participants

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 21; 22; 11; 1 Participants

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade - (RSV-seropositive Participants) — 8; 5; 0; 0 Participants

Primary: Area Under the Curve (AUC) for RSV-A Memphis 37b Viral Load Determined by Quantitative Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) — 350.99…

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 0; 0 participants

Primary: Geometric Mean Fold Rise Against RSV Fa Protein — 12.5; 9.9 fold change — p=0.14

Primary: Number of Hospital Admissions by Respiratory Syncytial Virus Infection — 2 participants

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 17; 9; 3; 1 Participants

Primary: Number of Participants With Unsolicited Treatment Emergent Adverse Events (TEAEs) Through Day 151 — 1; 2; 3; 3 Participants

Primary: Area Under the Viral Load-time Curve (VL-AUC) of RSV — 0.00; 96.65 h*log10 PFU/mL

Primary: Host Response to RSV Challenge Measured as Change From Baseline of Chemical Mediators in Nasal Fluid — 23 Participants

Primary: Part A: RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs) — 11910.1; 8593.6 Titer

Primary: Frequency of Grade 1 or Higher Solicited Adverse Events (AEs) by Grade — 14; 7; 27; 11 Participants

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 16; 10; 0; 0 Participants

Primary: Number of Participants Who Experienced the Occurrence of a Third Episode of Post-RSV Wheezing (Recurrent Wheeze) — 45; 33 Participants — p=0.08

Primary: Number of Maternal Subjects With Pregnancy Outcomes — 2088; 18; 8; 5 Participants

Primary: Geometric Mean Titer (GMT) of Serum Neutralizing Titers (NTs) for Respiratory Syncytial Virus Subgroup A (RSV A) and Respiratory Syncytial Virus Subgroup B (RSV B)…

Primary: RSV-A Serum Neutralizing Titers Expressed As Mean Geometric Increase (MGI) Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group — 1.34 Ratio

Primary: Number of Solicited and Unsolicited Adverse Events (AEs) — 17 adverse events

Primary: Number of Participants With Solicited Symptoms — 6; 4; 15; 7 participants

Primary: Time-Weighted Average Change in Respiratory Syncytial Viral (RSV) Load From Baseline to Day 5 — -0.77; -0.89 log10 copies/mL — p=0.46